Breast cancer is one of the most diagnosed cancer worldwide, it is responsible for the highest cancer related mortality rate among women in less developed countries and 2nd beside lung cancer in developed countries. Concerns regarding this fact have resulted in a well screening program as a secondary preventive measure, which was introduced parallel to the succeeding studying of the molecular level and immunological activity of breast cancer, that further allows progress in developing various treatment approaches mainly in biological treatment resulting in a noticeable decrease in recurrent rate along with increase in the survival rate of breast cancer. Taking a look among the oldest biological agent, HER2 targeting agents show significant efficacy among HER2+ overexpression tumors, which count only for a small percentage of breast cancer. However, considering other tumor characteristics like triple negative tumors, moreover, those HER2+ relapsing or resistant tumors under HER2 directed therapies, a number of new immune modulatory agents like anti PDL1 are developing nowadays and undergoing clinical trials to show promising results.